BeiGene, Ltd. (BGNE): Stock Offering News

BGNE – Prices 2.465 mln ADS’s at $71.00 per ADS.


Key Facts Surrounding This News Item


  • BGNE had a POWR Rating of B (Buy) coming into today.
  • BGNE was -1.31% below its 10-Day Moving Average coming into today.
  • BGNE was -1.78% below its 20-Day Moving Average coming into today.
  • BGNE was 23.79% above its 50-Day Moving Average coming into today.
  • BGNE was 50.51% above its 100-Day Moving Average coming into today.
  • BGNE was 76.74% above its 200-Day Moving Average coming into today.
  • BGNE had returned +139.26% year-to-date leading up to today’s news, versus a +10.06% return from the benchmark S&P 500 during the same period.

More Info About BeiGene, Ltd. (BGNE)


BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands. View our full BGNE ticker page with ratings, news, and more.

BGNE at a Glance

BGNE Current POWR Rating™
Overall POWR Rating™
BGNE Current Price $93.11 1.88%
More BGNE Ratings, Data, and News

BGNE Price Reaction

The day of this event (Aug. 11, 2017)
BGNE Closing Price$71.02 2.23%
BGNE Volume770,200
476.15% from avg
Leading up to this event
BGNE 1-mo return1.69%
After this event
BGNE 1-day return1.81%
BGNE 3-day return3.74%
BGNE 5-day return9.74%

BGNE Price Chart



More BeiGene, Ltd. (BGNE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All BGNE News
Page generated in 0.859 seconds.